The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 20, 2024
Filed:
May. 28, 2019
Applicant:
Hua Medicine (Shanghai) Ltd., Shanghai, CN;
Inventors:
Li Chen, Shanghai, CN;
Yongguo Li, Shanghai, CN;
Gaosen Wang, Shanghai, CN;
Huisheng Gao, Shanghai, CN;
Assignee:
HUA Medicine (Shanghai) Ltd., Shanghai, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/20 (2006.01); A61K 9/16 (2006.01); A61K 9/28 (2006.01); A61K 31/155 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01); A61K 31/4035 (2006.01); A61K 31/4155 (2006.01); A61K 31/4439 (2006.01); A61K 31/4985 (2006.01); A61K 31/522 (2006.01); A61K 31/7034 (2006.01); A61K 45/06 (2006.01); A61K 47/38 (2006.01); A61P 3/10 (2006.01); C07D 231/38 (2006.01); C07D 403/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4155 (2013.01); A61K 9/1611 (2013.01); A61K 9/1617 (2013.01); A61K 9/1635 (2013.01); A61K 9/1694 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2086 (2013.01); A61K 9/2095 (2013.01); A61K 9/2813 (2013.01); A61K 9/284 (2013.01); A61K 9/2866 (2013.01); A61K 31/155 (2013.01); A61K 31/40 (2013.01); A61K 31/403 (2013.01); A61K 31/4035 (2013.01); A61K 31/4439 (2013.01); A61K 31/4985 (2013.01); A61K 31/522 (2013.01); A61K 31/7034 (2013.01); A61K 45/06 (2013.01); A61K 47/38 (2013.01); A61P 3/10 (2018.01); C07D 231/38 (2013.01); C07D 403/12 (2013.01);
Abstract
The present invention relates to a pharmaceutical combination. The pharmaceutical combination comprises a glucose kinase activator or a pharmaceutical salt of same, an isotope marker of same, a crystal form, hydrate, solvate, diastereomer or enantiomer form of same, and a PPAR receptor activator. The present invention further relates to a pharmaceutical composition, a fixed-dose compound preparation, and a preparation method for and uses of the pharmaceutical composition and of the fixed dose compound preparation.